Sanofi Confident In Beyfortus Achieving Blockbuster Status In 2024

Foresees Strength Versus Future RSV Antibody Competitor

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Beyfortus was a minimal contributor in Sanofi’s second quarter, which beat consensus and prompted an earnings guidance boost, but the RSV antibody’s sales should surge in Q3 and Q4.

Sanofi logo at a skyscraper in Warsaw, Poland
Beyfortus and Dupixent bookended Sanofi's sales in terms of lowest and highest sellers in Q2 • Source: Shutterstock

Sanofi fully expects its preventive respiratory syncytial virus (RSV) antibody for infants, Beyfortus (nirsevimab), to achieve blockbuster status in 2024 – its first full year on the market in the US – the company’s executives said during a 25 July presentation of second quarter sales and earnings. While Beyfortus was a minimal contributor to Sanofi’s higher-than-expected Q2 revenue, the company expects sales to surge in Q3 and grow even further in Q4.

Key Takeaways

  • Sanofi expects sales of its RSV preventive antibody Beyfortus to surge in Q3 and Q4 with the start of the 2024-2025 RSV season, making nirsevimab a blockbuster in its first full year on the market.

With €10.75bn ($11.66bn) in Q2 revenue, which exceeded analyst consensus and represented a 10.2% year-over-year increase on a constant exchange...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Nabil

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains